Phase 2 Recurrent or Metastatic Clinical Trials
20 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 20 trials
Recruiting
Phase 1Phase 2
Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma
Recurrent or Metastatic Esophageal AdenocarcinomaBiomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Beijing Biotech36 enrolled1 locationNCT07622940
Recruiting
Phase 1Phase 2
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaBiomarker-positive EGFR/HER2- Expressing HNSCC
Beijing Biotech42 enrolled1 locationNCT07617805
Recruiting
Phase 2
Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen33 enrolled1 locationNCT07581821
Recruiting
Phase 1Phase 2
Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers
HPV 16+ Recurrent or Metastatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins24 enrolled1 locationNCT04713046
Recruiting
Phase 2
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Recurrent or Metastatic Solid Tumors
Daiichi Sankyo520 enrolled119 locationsNCT06330064
Recruiting
Phase 1Phase 2
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Recurrent or Metastatic Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.202 enrolled20 locationsNCT07258979
Recruiting
Phase 2
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.60 enrolled2 locationsNCT07051486
Recruiting
Phase 2
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen208 enrolled6 locationsNCT07070479
Recruiting
Phase 2
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Locally Advanced, Recurrent or Metastatic Malignancies
Shenyang Sunshine Pharmaceutical Co., LTD.340 enrolled1 locationNCT07022002
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Shanghai Miracogen Inc.116 enrolled1 locationNCT04868162
Recruiting
Phase 1Phase 2
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.100 enrolled1 locationNCT06859775
Recruiting
Phase 2
Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N
Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Groupe Oncologie Radiotherapie Tete et Cou70 enrolled1 locationNCT06640725
Recruiting
Phase 2
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Recurrent or Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University56 enrolled1 locationNCT06657690
Recruiting
Phase 2
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen32 enrolled1 locationNCT06472713
Recruiting
Phase 2
Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
Advanced Non Small Cell Lung Cancer (NSCLC)Third-line and Beyond TherapyRecurrent or Metastatic Lung Cancer+1 more
Li-kun Chen32 enrolled1 locationNCT06728852
Recruiting
Phase 2
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Endometrial CarcinomaTP53 MutationRecurrent or Metastatic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences117 enrolled1 locationNCT06413992
Recruiting
Phase 2Phase 3
A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Recurrent or Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University300 enrolled1 locationNCT06241599
Completed
Phase 2
Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms
Hormone sensitive recurrent or metastatic gynecological cancers
University of Sydney350 enrolled3 locationsACTRN12610000796088
Completed
Phase 2
ANZ 0601 / CIRG/TORI 010
HER2 Negative Locally Recurrent or Metastatic Breast Cancer
Amgen Inc.273 enrolled1 locationACTRN12606000507583
Completed
Phase 2
ATTAX
Locally recurrent or metastatic oesophago-gastric cancer
Australasian Gastro-Intestinal Trials Group A(AGITG)100 enrolled1 locationACTRN12606000163505